Jonathan Erlich

Regulation of an essential innate immune response by the p50 subunit of NF-kappaB.

Jan Bohuslav, Vladimir V. Kravchenko, Graham C. Parry et al. · Journal of Clinical Investigation · 1998 · 276 citations · Full text

P50 Subunit, Innate Immune System, Immunology +16

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Low levels of tissue factor are compatible with development and hemostasis in mice.

Graham C. Parry, Jonathan Erlich, Peter Carmeliet et al. · Journal of Clinical Investigation · 1998 · 202 citations · Full text

Inflammation, Knockout Mouse, Tissue Development +15

Inhibition of the Tissue Factor-Thrombin Pathway Limits Infarct Size after Myocardial Ischemia-Reperfusion Injury by Reducing Inflammation

Jonathan Erlich, Edward M. Boyle, Joanne Labriola et al. · American Journal Of Pathology · 2000 · 191 citations · Full text

Inflammation, Thrombosis, Cardiovascular Disease +11